PDGFRB and glioblastoma: Despite the central role of PDGFR and related RTKs in GBM pathogenesis, clinical trials with multitargeted kinase and PDGFR inhibitors, such as imatinib, tivozanib, and nilotinib, failed to extend survival [56,57,58,59].